These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38032853)

  • 1. Effectiveness of a fourth SARS-CoV-2 vaccine dose in previously infected individuals from Austria.
    Chalupka A; Richter L; Chakeri A; El-Khatib Z; Theiler-Schwetz V; Trummer C; Krause R; Willeit P; Benka B; Ioannidis JPA; Pilz S
    Eur J Clin Invest; 2024 Mar; 54(3):e14136. PubMed ID: 38032853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of the First and Second Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Dose: A Nationwide Cohort Study From Austria on Hybrid Versus Natural Immunity.
    Chalupka A; Riedmann U; Richter L; Chakeri A; El-Khatib Z; Sprenger M; Theiler-Schwetz V; Trummer C; Willeit P; Schennach H; Benka B; Werber D; Høeg TB; Ioannidis JPA; Pilz S
    Open Forum Infect Dis; 2024 Oct; 11(10):ofae547. PubMed ID: 39371370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative effectiveness of COVID-19 vaccination with 3 compared to 2 doses against SARS-CoV-2 B.1.1.529 (Omicron) among an Australian population with low prior rates of SARS-CoV-2 infection.
    Liu B; Gidding H; Stepien S; Cretikos M; Macartney K
    Vaccine; 2022 Oct; 40(43):6288-6294. PubMed ID: 36180375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody levels following vaccination against SARS-CoV-2: associations with post-vaccination infection and risk factors in two UK longitudinal studies.
    Cheetham NJ; Kibble M; Wong A; Silverwood RJ; Knuppel A; Williams DM; Hamilton OKL; Lee PH; Bridger Staatz C; Di Gessa G; Zhu J; Katikireddi SV; Ploubidis GB; Thompson EJ; Bowyer RCE; Zhang X; Abbasian G; Garcia MP; Hart D; Seow J; Graham C; Kouphou N; Acors S; Malim MH; Mitchell RE; Northstone K; Major-Smith D; Matthews S; Breeze T; Crawford M; Molloy L; Kwong ASF; Doores K; Chaturvedi N; Duncan EL; Timpson NJ; Steves CJ
    Elife; 2023 Jan; 12():. PubMed ID: 36692910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
    Haas EJ; Angulo FJ; McLaughlin JM; Anis E; Singer SR; Khan F; Brooks N; Smaja M; Mircus G; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
    Lancet; 2021 May; 397(10287):1819-1829. PubMed ID: 33964222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 infection following booster vaccination: Illness and symptom profile in a prospective, observational community-based case-control study.
    Antonelli M; Penfold RS; Canas LDS; Sudre C; Rjoob K; Murray B; Molteni E; Kerfoot E; Cheetham N; Pujol JC; Polidori L; May A; Wolf J; Modat M; Spector T; Hammers A; Ourselin S; Steves C
    J Infect; 2023 Dec; 87(6):506-515. PubMed ID: 37777159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk and symptoms of COVID-19 in health professionals according to baseline immune status and booster vaccination during the Delta and Omicron waves in Switzerland-A multicentre cohort study.
    Babouee Flury B; Güsewell S; Egger T; Leal O; Brucher A; Lemmenmeier E; Meier Kleeb D; Möller JC; Rieder P; Rütti M; Schmid HR; Stocker R; Vuichard-Gysin D; Wiggli B; Besold U; McGeer A; Risch L; Friedl A; Schlegel M; Kuster SP; Kahlert CR; Kohler P;
    PLoS Med; 2022 Nov; 19(11):e1004125. PubMed ID: 36342956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness of different primary vaccination courses on mRNA-based booster vaccines against SARs-COV-2 infections: a time-varying cohort analysis using trial emulation in the Virus Watch community cohort.
    Nguyen VG; Yavlinsky A; Beale S; Hoskins S; Byrne TE; Lampos V; Braithwaite I; Fong WLE; Fragaszy E; Geismar C; Kovar J; Navaratnam AMD; Patel P; Shrotri M; Weber S; Hayward AC; Aldridge RW
    Int J Epidemiol; 2023 Apr; 52(2):342-354. PubMed ID: 36655537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
    Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM
    Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of bivalent mRNA vaccines against medically attended symptomatic SARS-CoV-2 infection and COVID-19-related hospital admission among SARS-CoV-2-naive and previously infected individuals: a retrospective cohort study.
    Tan CY; Chiew CJ; Pang D; Lee VJ; Ong B; Wang LF; Ren EC; Lye DC; Tan KB
    Lancet Infect Dis; 2023 Dec; 23(12):1343-1348. PubMed ID: 37543042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Effectiveness of COVID-19 Bivalent Versus Monovalent mRNA Vaccines in the Early Stage of Bivalent Vaccination in Korea: October 2022 to January 2023.
    Kim RK; Choe YJ; Jang EJ; Chae C; Hwang JH; Lee KH; Shim JA; Kwon GY; Lee JY; Park YJ; Lee SW; Kwon D
    J Korean Med Sci; 2023 Nov; 38(46):e396. PubMed ID: 38013649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High vaccine effectiveness against severe COVID-19 outcomes and population preventable fraction during the Omicron era in Luxembourg: A nationwide retrospective risk factor analysis.
    Bejko D; Ernst C; Vergison A; Stranges S; Zeegers MP; Mossong J
    Vaccine; 2024 Sep; 42(22):126011. PubMed ID: 38825555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
    Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
    PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of diabetes following COVID-19 vaccination and SARS-CoV-2 infection in Hong Kong: A population-based cohort study.
    Xiong X; Lui DTW; Chung MSH; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Cheng FWT; Cheung CL; Chan EWY; Lee CH; Woo YC; Tan KCB; Wong CKH; Wong ICK
    PLoS Med; 2023 Jul; 20(7):e1004274. PubMed ID: 37486927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing real-world vaccine effectiveness against severe forms of SARS-CoV-2 infection: an observational study from routine surveillance data in Switzerland.
    Anderegg N; Althaus CL; Colin S; Hauser A; Laube A; Mäusezahl M; Wagner M; Zaffora B; Riou J
    Swiss Med Wkly; 2022 Apr; 152():w30163. PubMed ID: 35752951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative Effectiveness of Coronavirus Disease 2019 Vaccination and Booster Dose Combinations Among 18.9 Million Vaccinated Adults During the Early Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Period-United States, 1 January 2022 to 31 March 2022.
    Kompaniyets L; Wiegand RE; Oyalowo AC; Bull-Otterson L; Egwuogu H; Thompson T; Kahihikolo K; Moore L; Jones-Jack N; El Kalach R; Srinivasan A; Messer A; Pilishvili T; Harris AM; Gundlapalli AV; Link-Gelles R; Boehmer TK
    Clin Infect Dis; 2023 May; 76(10):1753-1760. PubMed ID: 36750643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study.
    Jara A; Undurraga EA; Zubizarreta JR; González C; Pizarro A; Acevedo J; Leo K; Paredes F; Bralic T; Vergara V; Mosso M; Leon F; Parot I; Leighton P; Suárez P; Rios JC; García-Escorza H; Araos R
    Lancet Glob Health; 2022 Jun; 10(6):e798-e806. PubMed ID: 35472300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of Messenger RNA-1273 Vaccine Booster Against Coronavirus Disease 2019 in Immunocompetent Adults.
    Florea A; Sy LS; Qian L; Ackerson BK; Luo Y; Tubert JE; Lee GS; Ku JH; Bruxvoort KJ; Talarico CA; Qiu S; Tian Y; Tseng HF
    Clin Infect Dis; 2023 Jan; 76(2):252-262. PubMed ID: 36134518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BNT162b2 vaccine protection against omicron and effect of previous infection variant and vaccination sequence among children and adolescents in Singapore: a population-based cohort study.
    Yung CF; Pang D; Kam KQ; Lye DC; Ong B; Chong CY; Tan KB
    Lancet Child Adolesc Health; 2023 Jul; 7(7):463-470. PubMed ID: 37201540
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.